1
|
Oka S, Ikeda K, Takano M, Ogane M, Tanuma J, Tsukada K, Gatanaga H. Pathogenesis, clinical course, and recent issues in HIV-1-infected Japanese hemophiliacs: a three-decade follow-up. Glob Health Med 2020; 2:9-17. [PMID: 33330768 PMCID: PMC7731362 DOI: 10.35772/ghm.2019.01030] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2019] [Revised: 01/28/2020] [Accepted: 02/03/2020] [Indexed: 11/08/2022]
Abstract
Nearly 30% of Japanese hemophiliacs were infected with HIV-1 in the early 1980s. They have unique characteristics compared to HIV-1-infected individuals through other routes, including date of infection of 1986 or earlier, mean age of nearly 50 years, and common co-infection with hepatitis C, but rarely with other sexually transmitted diseases. Antiretroviral therapy (ART) was introduced in Japan in 1997. The clinical courses before and after 1997 were quite different. Careful analysis of the pre-1997 clinical data allowed expansion of our knowledge about the natural course and pathogenesis of the disease. Switching to the second receptor agents proved critical in subsequent disease progression. HIV-1 continued to escape immune pressure, pushing disease progression faster. In contrast, ART was effective enough to overcome the natural course. Prognosis improved dramatically and cause of death changed from AIDS-related opportunistic infections and malignancies before 1997, to hepatitis C virus-related cirrhosis and hepatocellular carcinoma (HCC) around 2010, and again to non-AIDS defining malignancies recently. In most cases, hepatitis C was cured with direct acting antiviral therapy. However, HCV progressed to cirrhosis in some cases and risk of HCC is still high among these patients. Together with improvement in anticoagulants and aging of the patients, risk of myocardial infarction has increased recently. In addition, the numbers of patients with life-style related co-morbidities, such as diabetes mellitus, hypertension, and chronic kidney disease have been also increasing. Finally, stigma is still an important barrier to a better life in HIV-1-positive individuals.
Collapse
Affiliation(s)
- Shinichi Oka
- AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kazuko Ikeda
- AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Misao Takano
- AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Miwa Ogane
- AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Junko Tanuma
- AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kunihisa Tsukada
- AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Hiroyuki Gatanaga
- AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan
| |
Collapse
|
2
|
van de Putte DEF, Fischer K, Roosendaal G, Hoepelman AIM, Mauser-Bunschoten EP. Morbidity and mortality in ageing HIV-infected haemophilia patients. Haemophilia 2012; 19:141-9. [DOI: 10.1111/j.1365-2516.2012.02912.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/17/2012] [Indexed: 11/30/2022]
Affiliation(s)
- D. E. Fransen van de Putte
- Van Creveldkliniek; Department of Haematology; University Medical Center Utrecht; Utrecht; The Netherlands
| | | | - G. Roosendaal
- Van Creveldkliniek; Department of Haematology; University Medical Center Utrecht; Utrecht; The Netherlands
| | - A. I. M. Hoepelman
- Department of Internal Medicine and Infectious Diseases; University Medical Center Utrecht; Utrecht; The Netherlands
| | - E. P. Mauser-Bunschoten
- Van Creveldkliniek; Department of Haematology; University Medical Center Utrecht; Utrecht; The Netherlands
| |
Collapse
|
3
|
Weisshaar CL, Winer JP, Guarino BB, Janmey PA, Winkelstein BA. The potential for salmon fibrin and thrombin to mitigate pain subsequent to cervical nerve root injury. Biomaterials 2011; 32:9738-46. [PMID: 21944723 DOI: 10.1016/j.biomaterials.2011.09.021] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2011] [Accepted: 09/07/2011] [Indexed: 01/23/2023]
Abstract
Nerve root compression is a common cause of radiculopathy and induces persistent pain. Mammalian fibrin is used clinically as a coagulant but presents a variety of risks. Fish fibrin is a potential biomaterial for neural injury treatment because it promotes neurite outgrowth, is non-toxic, and clots readily at lower temperatures. This study administered salmon fibrin and thrombin following nerve root compression and measured behavioral sensitivity and glial activation in a rat pain model. Fibrin and thrombin each significantly reduced mechanical allodynia compared to injury alone (p < 0.02). Painful compression with fibrin exhibited allodynia that was not different from sham for any day using stimulation by a 2 g filament; allodynia was only significantly different (p < 0.043) from sham using the 4 g filament on days 1 and 3. By day 5, responses for fibrin treatment decreased to sham levels. Allodynia following compression with thrombin treatment were unchanged from sham at any time point. Macrophage infiltration at the nerve root and spinal microglial activation were only mildly modified by salmon treatments. Spinal astrocytic expression decreased significantly with fibrin (p < 0.0001) but was unchanged from injury responses for thrombin treatment. Results suggest that salmon fibrin and thrombin may be suitable biomaterials to mitigate pain.
Collapse
Affiliation(s)
- Christine L Weisshaar
- Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104-6321, USA.
| | | | | | | | | |
Collapse
|
4
|
MANGIAFICO L, PERJA M, FUSCO F, RIVA S, MAGO D, GRINGERI A. Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance. Haemophilia 2011; 18:108-11. [DOI: 10.1111/j.1365-2516.2011.02610.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
MAUSER-BUNSCHOTEN EP, FRANSEN VAN DE PUTTE DE, SCHUTGENS REG. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia 2009; 15:853-63. [DOI: 10.1111/j.1365-2516.2009.01987.x] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
6
|
Liras A. Disorder in clotting pattern after antiretroviral treatment with emtricitabine in an HIV-positive haemophiliac patient. Clin Drug Investig 2007; 27:857-9. [PMID: 18020544 DOI: 10.2165/00044011-200727120-00008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Hepatitis C virus and human immunodeficiency virus (HIV) co-infection is a major problem for haemophiliacs treated before 1985 with non-virally inactivated clotting factor concentrates. Over the past 10 years, the management of HIV infection has been better standardised by optimisation of highly active antiretroviral therapy, which leads to suppression of viral load and increases the number of CD4+ T cells. However, despite HIV infection being effectively controlled, patients experience short- and long-term adverse effects. This report describes a disorder in the clotting pattern with a decrease (approximately 60%) in the efficiency of antihaemophilic factor infusion after antiretroviral treatment with emtricitabine (a reverse transcriptase inhibitor) in an HIV-positive haemophiliac patient.
Collapse
Affiliation(s)
- Antonio Liras
- Scientific Commission of the Royal Foundation 'Victoria Eugenia' of Haemophilia, Madrid, Spain.
| |
Collapse
|
7
|
Yoong D, Loufty M, Chin T, Bayoumi AM. Severe bruising in an HIV-positive patient with haemophilia after using a needle-free gas-powered injection device. AIDS 2007; 21:1499-500. [PMID: 17589206 DOI: 10.1097/qad.0b013e3282364663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Abstract
PURPOSE Apoptosis during HIV infection has been evoked for ten years. The role of apoptosis during HIV infection have be confirmed by several authors but the exact relationships between viral replication, apoptosis and lymphocyte depletion remain to be clarified. CURRENT KNOWLEDGE AND KEY POINTS HIV may induce apoptosis of infected but also of uninfected bystander CD4+ lymphocytes. Those two types of HIV induced apoptosis lie on different pathways. While Fas and FasL are involved in apoptosis of bystander cells, mitochondrial pathway is required for apoptosis of infected cells. Cytokines but also anti HIV drugs may modulate HIV-induced lymphocyte apoptosis. Morever while protease inhibitor influence HIV replication and then secondary apotosis of infected cells, they can also interfere with spontaneous apoptosis of lymphocyte beside the context of HIV infection. FUTURES AND PROJECTS Apoptosis is thought to be one of the mechanism involved in CD4 T lymphocyte cell death during HIV infection. However relationships between apoptosis and HIV replication may be more complex. In fact it has been recently reported that while HIV replication induced lymphocyte apoptosis, apoptosis may in turn induced HIV replication in a loop amplification pathway
Collapse
Affiliation(s)
- J-D Lelièvre
- EMI-U 9922 Inserm/université Paris VII, IFR02, AP-HP, faculté de médecine Xavier-Bichat, 16, rue Henri-Huchard, 75018 Paris, France.
| | | | | | | |
Collapse
|
9
|
Abstract
Haemophilia care and treatment products have greatly improved over the past 2 decades. Transitions in treatment produced by these changes were accompanied by the emergence of unexpected risks and new complications. In order to provide the best comprehensive care to patients with haemophilia, healthcare providers periodically need to re-evaluate and adjust their management and therapeutic products to prevent or minimize the effects produced by the emerging issues. For example, reducing the effects of infectious agents remains the highest priority for the haemophilia community because of the high level of morbidity and mortality that has resulted from earlier therapeutic agents. In many countries, the goal has been to achieve absolute zero risk for infectious agents. In some instances, the screening procedures to achieve these goals reduced the availability of plasma needed for manufactured derivatives and produced another emerging risk, shortages of clotting factor preparations. Similarly, better diagnostic methods identified other potential agents that were not inactivated by current technology. Likewise, immune tolerance regimens and the prophylactic management of haemophilia introduced different therapeutic delivery systems with their own risks. The drugs used to manage diseases such as human immunodeficiency virus (HIV), which were transmitted by products manufactured before mid-1980, create their own set of risks for this community. Topical emerging risks of treatment, including variant Creutzfeldt-Jakob disease, an assessment of its risks and impact, the complications of using indwelling catheters, and the role of protease inhibitors used to treat HIV may have on bleeding complications of haemophilia are discussed.
Collapse
Affiliation(s)
- B L Evatt
- Hematologic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
| | | | | | | |
Collapse
|
10
|
Abstract
The pandemic created by HIV, a retrovirus, has stimulated increased research in viral diseases and has generated greater interest in the development of antiretroviral medications. These new medications are presently divided into 3 categories: protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside reverse transcriptase inhibitors (NRTIs). These antiretroviral agents carry their own risk for causing adverse reactions, as well as drug interactions. The most recently approved class of antiretrovirals, PIs have been associated with lipodystrophy syndrome, hypersensitivity reactions, urticaria, morbilliform eruptions, and a large number of drug interactions. NNRTIs have resulted in various cutaneous eruptions, as well as a hypersensitivity syndrome. NRTIs have resulted in alterations of the nails, nail and mucocutaneous pigmentation, hair changes, vasculitis, and morbilliform eruptions. This article focuses on the cutaneous manifestations of antiretroviral therapy to help dermatologists recognize them.
Collapse
Affiliation(s)
- Holly A Ward
- Department of Dermatology, Tulane University School of Medicine, New Orleans, LA 70112, USA
| | | | | |
Collapse
|
11
|
Kodoth S, Bakshi S, Scimeca P, Black K, Pahwa S. Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac. AIDS Patient Care STDS 2001; 15:347-52. [PMID: 11483161 DOI: 10.1089/108729101750301898] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The use of protease Inhibitors (PI) has been associated with many adverse effects including increased tendency to bleed, which is particularly problematic in individuals with congenital coagulation disorders. We report the occurrence of spontaneous intracranial bleeding in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving amprenavir (APV). The bleeding resolved on discontinuation of APV. This case report highlights a need for awareness of increased bleeding as a potentially serious complication associated with the use of all currently licensed PIs in individuals with hemophilia.
Collapse
Affiliation(s)
- S Kodoth
- Department of Pediatric Allergy and Immunology, Northshore University Hospital, NYU School of Medicine, Manhasset, New York 11030, USA
| | | | | | | | | |
Collapse
|
12
|
Abstract
Saquinavir is a peptidomimetic inhibitor of HIV protease. Initially marketed as Invirasetrade mark, the effectiveness of saquinavir was greatly hindered by its nearly complete first pass metabolism by cytochrome P450 3A4. A new formulation, Fortovasetrade mark, appears to yield some six times the drug exposure and has been demonstrated to yield virological and immunological results similar to those of other protease inhibitors (PIs) when used in conjunction with two nucleoside reverse transcriptase inhibitors (nRTIs). Emerging data suggest it is safe to use twice daily. Co-administration of either formulation of saquinavir with nelfinavir and especially ritonavir yields greatly increased blood levels, with corresponding superior magnitude and durability of viral suppression in first line therapy, albeit with increased adverse effects. The combination of ritonavir and saquinavir has also yielded the most promising results published for second line therapy, after virological breakthrough on previous PI-containing therapy. In addition, preliminary data suggests the possibility of once daily dosing of ritonavir and saquinavir, which would be expected to increase compliance and allow for direct observed therapy.
Collapse
Affiliation(s)
- S Kravcik
- Division of General Medicine, Ottawa Hospital, General Campus, Canada
| |
Collapse
|
13
|
Abstract
Antiretroviral toxicity is an increasingly important issue in the management of HIV-infected patients. With the sustained major declines in opportunistic complications, HIV infection is a more chronic disease, and so more drugs are being used in more patients for longer periods. This review focuses on the pathogenesis, clinical features, and management of the principal toxicities of the 15 licensed antiretroviral drugs, including mitochondrial toxicity, hypersensitivity, and lipodystrophy, as well as more drug-specific adverse effects and special clinical settings.
Collapse
Affiliation(s)
- A Carr
- HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital, Sydney, New South Wales, Australia.
| | | |
Collapse
|
14
|
Abstract
Shortly after the introduction of protease inhibitor drugs (PIs) for the treatment of human immunodeficiency virus infection an association between these drugs and an increased bleeding tendency in patients with hereditary bleeding disorders was observed. Not only do patients experience an increased bleed frequency in usual sites, but bleeds can also occur in unusual places such as the finger joints. Mucus membrane bleeding and haematuria are also common. Ritonavir appears to be associated with the highest risk of bleeding followed by indinavir. As yet there has not been enough experience with the newer PIs to assess fully their potential to induce increased bleeding, although nelfinavir seems to pose less of a risk than the original PIs. PI-associated bleeds tend to be more resistant to factor concentrate treatment and periods of prophylaxis may be required in individuals with frequent persistent bleeds. Patients continuing on PI therapy tend to develop a tolerance to this adverse effect with time. The mechanism of the bleeding tendency has not been elucidated. There is no consistent evidence of a disturbance of coagulation, fibrinolysis or platelet function which raises the possibility that PIs may exert a direct local effect on blood vessels. It is very important that this class-specific side-effect is recognized and understood by both treaters and patients.
Collapse
Affiliation(s)
- J T Wilde
- West Midlands Adult Comprehensive Care Haemophilia Centre, University Hospital Birmingham NHS Trust, Edgbaston, Birmingham B15 2TH, UK.
| |
Collapse
|
15
|
Wilde JT, Lee CA, Collins P, Giangrande PL, Winter M, Shiach CR. Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders. Br J Haematol 1999; 107:556-9. [PMID: 10583257 DOI: 10.1046/j.1365-2141.1999.01748.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The use of protease inhibitor (PI) drugs in treatment regimens for HIV-infected patients with hereditary bleeding disorders has been associated with an increased bleeding tendency. To characterize the nature of this bleeding tendency, a retrospective case record analysis was performed on 67 HIV-positive patients with hereditary bleeding disorders who had been treated with PI therapy. 34 patients (51%) developed an increased bleeding tendency on PI therapy, usually within the first few weeks of treatment. As well as an increase in usual joint bleeds, patients developed spontaneous atypical small joint, soft tissue and muscle bleeds. Haematuria was also common. Bleeding episodes tended to respond suboptimally to factor concentrate replacement. Ritonavir was most likely to be associated with bleeding. Nine patients switched first-line PI therapy as a direct consequence of bleeding and seven had no further bleeding problem on their second PI. Factor concentrate usage was significantly increased during the first 6 months of PI therapy compared to the 6 months preceeding treatment. PI therapy is frequently associated with increased bleeding in patients with hereditary bleeding disorders. The mechanism of the bleeding tendency remains to be elucidated.
Collapse
Affiliation(s)
- J T Wilde
- West Midlands Adult Comprehensive Care Haemophilia Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham.
| | | | | | | | | | | |
Collapse
|
16
|
Abstract
The use of triple regimens, often called highly active antiretroviral therapy (HAART), generally involving 2 nucleoside analogues and an HIV protease inhibitor, have been endorsed as the standard of care for persons with HIV initiating therapy by a number of sets of international guidelines. The widespread availability of protease inhibitor-containing regimens has been associated with a dramatic drop in the incidence of new AIDS events and mortality throughout the developed world. Use of HAART regimens, particularly in treatment-naïve individuals, is also associated with dramatic reductions in HIV RNA load, rises in CD4+ cell numbers and improvements in some aspects of immune function. However, protease inhibitor therapy is associated with a range of adverse effects, which varies between agents, and regimens frequently involve inconvenient administration schedules and disruption to patient's lives. Thus, the undoubted benefits of antiretroviral therapy come at some cost in terms of both physical and psychological morbidity to the recipient. In assessing an individual for therapy, consideration of the risk of disease events and the benefit of therapy in reducing or preventing these events must be weighed against the potential of therapy to cause morbidity. Using these criteria, we suggest that an individual with a 3 year risk of disease progression of less than 10% (based on CD4+ cell count and HIV RNA load) is more likely to a experience a morbidity if treated with HAART than if left untreated and monitored. For individuals with higher risks of HIV progression the risk versus benefit of initiating therapy may, in many cases, still be in favour of no therapy and continued observation. This will vary depending on the individuals risks (such as family and past medical history) and on the choice of agents in the regimen, some regimens having greater risks than others.
Collapse
Affiliation(s)
- G J Moyle
- Chelsea and Westminster Hospital, London, England
| | | |
Collapse
|